2seventy bio (BMV:TSVT *) - Stock Price, News & Analysis

TSVT * Stock Overview

A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.

About the company

TSVT * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 15.99% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

2seventy bio, Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$19.7b

XOMA Royalty

NasdaqGM:XOMA

US$329.9m

Shanghai MicuRx Pharmaceutical

SHSE:688373

CN¥2.4b

Emergent BioSolutions

NYSE:EBS

US$353.8m

Price History & Performance

Summary of all time highs, changes and price drops for 2seventy bio
Historical stock prices
Current Share Price	US$170.00
52 Week High	US$347.00
52 Week Low	US$167.00
Beta	0
11 Month Change	0%
3 Month Change	0%
1 Year Change	-69.26%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-80.09%

Recent updates

Shareholder Returns

	TSVT *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	-69.3%	0%	0%

Return vs Industry: TSVT * underperformed the MX Biotechs industry which returned -6% over the past year.

Return vs Market: TSVT * underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is TSVT *'s price volatile compared to industry and market?
TSVT * volatility
TSVT * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: TSVT * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TSVT *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2021	425	Nick Leschly	www.2seventybio.com

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company.

2seventy bio, Inc. Fundamentals Summary

How do 2seventy bio's earnings and revenue compare to its market cap?
TSVT * fundamental statistics
Market cap	Mex$5.89b
Earnings (TTM)	-Mex$3.64b
Revenue (TTM)	Mex$2.11b

2.8x

P/S Ratio

-1.6x

P/E Ratio

Is TSVT * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TSVT * income statement (TTM)
Revenue	US$124.69m
Cost of Revenue	US$272.99m
Gross Profit	-US$148.30m
Other Expenses	US$67.16m
Earnings	-US$215.46m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 14, 2023

Earnings per share (EPS)	-4.29
Gross Margin	-118.94%
Net Profit Margin	-172.80%
Debt/Equity Ratio	0%

How did TSVT * perform over the long term?

See historical performance and comparison

TSVT * Stock Overview

Rewards

Risk Analysis

2seventy bio, Inc. Competitors

BMV:LAB B

Mex$19.7b

NasdaqGM:XOMA

US$329.9m

SHSE:688373

CN¥2.4b

NYSE:EBS

US$353.8m

Price History & Performance

Recent News & Updates

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Recent updates

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

2seventy bio, Inc. Announces Executive and Board Changes

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces That Chip Baird Is Now Chief Operating Officer Expanding His Responsibilities to Include Finance, Corporate Development, Investor Relations and Corporate Communications as Well as Portfolio and Program/Alliance Management

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings released: US$1.08 loss per share (vs US$3.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

High number of new and inexperienced directors

President recently sold Mex$590k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

High number of new and inexperienced directors

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Second quarter 2022 earnings released: US$2.02 loss per share (vs US$3.60 loss in 2Q 2021)

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold Mex$1.8m worth of stock

President recently sold Mex$1.5m worth of stock

High number of new and inexperienced directors

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

High number of new and inexperienced directors

Shareholder Returns

Price Volatility

About the Company

2seventy bio, Inc. Fundamentals Summary

2.8x

-1.6x

Earnings & Revenue